Edit the instructions. Cefotaxime in powder form for the preparation of a solution for intravenous and intramuscular administration 250 mg, 500 mg, 1 g, 2 g

December 1, 2016
Active substances:
ICD-10:
I.A30-A49.A39    Meningococcal infection
I.A30-A49.A40    Streptococcal septicemia
I.A30-A49.A41    Other septicemia
I.A50-A64.A54    Gonococcal infection
I.A65-A69.A69.2    Lyme disease
X.J10-J18.J15    Bacterial pneumonia, not elsewhere classified
X.J20-J22.J20    Acute bronchitis
X.J40-J47.J42    Chronic bronchitis, unspecified
XI.K65-K67.K65.0    Acute peritonitis
XI.K80-K87.K81.0    Acute cholecystitis
XI.K80-K87.K81.1    Chronic cholecystitis
XI.K80-K87.K83.0    Cholangitis
XII.L00-L08.L01    Impetigo
XII.L00-L08.L02    Abscess of skin, boil and carbuncle
XII.L00-L08.L03    Phlegmon
XII.L00-L08.L08.0    Pyoderma
XIII.M00-M03.M00    Pyogenic arthritis
XIII.M86-M90.M86    Osteomyelitis
XIV.N10-N16.N10    Acute tubulointerstitial nephritis
XIV.N10-N16.N11    Chronic tubulointerstitial nephritis
XIV.N30-N39.N30    Cystitis
XIV.N30-N39.N34    Urethritis and urethral syndrome
XIV.N40-N51.N41    Inflammatory diseases of the prostate
XIV.N70-N77.N70    Salpingitis and oophoritis
XIV.N70-N77.N72    Inflammatory disease of the cervix
XIV.N70-N77.N71.9    Inflammatory disease of uterus, unspecified
XIX.T79.T79.3    Post-traumatic wound infection, not elsewhere classified
XXI.Z20-Z29.Z29.2    Another type of preventive chemotherapy
Cefotaxime, infectious and inflammatory diseases, peritonitis, sepsis, pelvic infections, lower respiratory tract infection, bone and joint infections, urinary tract infection, post-operative infection prevention, cephalosporin III generation

The need to supplement the instructions for the use of medicinal products with the following information is revealed:

1. In the "Contraindications" section, the information should be submitted in the following edition:

- Hypersensitivity to cefotaxime, other cephalosporins.

- For forms containing lidocaine as a solvent:

- hypersensitivity to lidocaine or other local anesthetic of the amide type;

- intracardiac blockades without an established pacemaker;

- severe heart failure;

- intravenous administration;

- children under the age of 2.5 years (intramuscular injection).